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Where Are the Diseases of
Clinical Significance?
It is perhaps surprising to state that we
have an extremely poor knowledge of the
global distribution of the vast majority of
infectious diseases [1]. A review of all
infectious diseases of clinical significance
has revealed it would be of public health
benefit to map about half of these
conditions; yet, astonishingly, only 2%
(seven of 355) have been mapped compre-
hensively [2]. This geographical ignorance
frustrates a variety of clinical, epidemio-
logical, and public health aspirations.
Here we argue that this information gulf
has serious implications for global public
health surveillance and that too little
attention is given to spatial epidemiology
in international preparedness planning.
Stated simply, how can we gauge the risk
posed by new infectious disease outbreaks
if we have only the crudest understanding
of their natural geographical range? Ad-
ditionally, how do we prioritise useful
intelligence in the growing deluge of Big
Data [3–5] if the contemporary geograph-
ical distribution of these infectious disease
threats is unknown? We suggest that it
should be a policy priority to improve the
ability to triage spatially, infectious disease
outbreak alerts [6,7].
How Do We Map Infectious
Diseases?
To explore the factors hindering prog-
ress, we need to consider how traditional
methods are used to map disease. We
illustrate this in Figure 1 using a schematic
of the cartographic process applied recent-
ly to map dengue [8,9]. The objective is to
make a continuous map of the entire
geographical range of a disease from a
sample of locations where the disease has
been observed [10,11]. In the ecological
literature this is described as identifying
the fundamental niche of the target
organism [12,13]. In our application it is
the fundamental niche of an infectious
disease. It is rare for any organism or
disease to fully exploit all of the environ-
mental space that is available to it, due to a
whole host of evolutionary, biogeograph-
ical and ecological factors, so to help guide
the mapping process we use evidence-
based expert knowledge to demark the
crude global limits of a disease—its
definitive extent or realised niche.
Figure 1 shows the process used to
generate a continuous data layer of disease
risk, in this example dengue. The process
starts with records of disease occurrence
obtained from the literature [14], web
reports [3], and GenBank [15] that are
used to define the definitive extent of the
disease [16] and to populate a database of
occurrence points where the disease has
been reported. Because it is rare for
disease absence to be recorded, a common
practice in niche mapping and modelling
is to infer absences [17,18]. The definitive
extent and occurrence point data are used
to infer plausible pseudo-absence points
for further analysis [9].
To complete the process illustrated in
Figure 1, a range of epidemiologically
relevant environmental covariates are also
assembled. These covariates, such as
temperature and rainfall, must cover the
area over which prediction is desired.
Statistical techniques are then used to
characterise points of presence and pseu-
do-absence against the range of covariates
assembled [8,9]. In this instance we
favoured the Boosted Regression Tree
technique due to favourable comparative
reviews of performance, statistical flexibil-
ity, and community support evidenced by
well documented and freely available R-
code [19,20]. These relationships are then
used to predict the probability that the
disease occurs at each location and
thereby generate a risk map with a
quantified measure of uncertainty.
Canonically, the output risk surface is
where the mapping process ends, which
further compounds the problem of the
paucity of infectious disease mapping. This
is in part due to the very labour intensive
nature of assembling (most often from the
peer-reviewed literature, for example, over
2,000 published articles contributed data
to the latest map of malaria vectors [21])
and then geo-positioning the required
information. Usually, trained analysts do
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Moreover, our strong perception of dis-
ease maps as static is clearly flawed
because disease risk can change rapidly
in space and in time and since knowledge
about the distribution of diseases now
improves daily [3–5,22,23], risk maps
become quickly outdated.
Can We Use Big Data
Approaches to Routinely Map
All of These Infectious
Diseases?
The process described above provides a
continuous risk map in space that is static
in time. Conversely HealthMap (www.
healthmap.org) provides continually up-
dated disease occurrence points but not
continuous spatial data. Can we conceive
of spatially continuous risk maps being
updated in ‘‘real-time’’—as frequently as
new occurrence data are assimilated? The
conceptual bridge of imagining spatial
modelling as a continuous process in time
is achieved simply by linking the output
risk map back to the data inputs to create a
feedback loop. This is important as it
facilitates the novel step of spatial triage of
new occurrence information (see below)
and critically, the potential for multiple
iterations of the map with continuous
improvement by adding a machine learn-
ing element. This conceptual shift towards
evolving maps, in combination with the
increased availability of novel digital data
sources [5,22], is now dissected in the
context of ‘‘Big Data.’’
Big Data is a term used to describe
information assemblages that make con-
ventional data, or database, processing
problematic due to any combination of
their size (volume), frequency of update
(velocity), or diversity (variety) [24]. These
‘‘volume, velocity, and variety’’ descriptors
have proven useful themes with which to
explore opportunities and challenges of
Big Data [24] and are emulated here.
Each part of this mapping process can be
radically improved with a Big Data
approach, and the extent of the Big Data
challenge is highlighted in Table 1. These
challenges are discussed in turn.
It is well established that a huge amount
of novel data are being generated that will
make important contributions to temporal
public health surveillance [5,22]. The
secondary use of passive search query
and micro-blogging data as well as actively
collected crowd-sourced data for disease
surveillance has been well documented
and validated for major public health
events, including influenza and dengue
Summary Points
N Systems to provide static spatially continuous maps of infectious disease risk
and continually updated reports of infectious disease occurrence exist but to-
date the two have never been combined.
N Novel online data sources, such as social media, combined with epidemiolog-
ically relevant environmental information are valuable new data sources that
can assist the ‘‘real-time’’ updating of spatial maps.
N Advances in machine learning and the use of crowd sourcing open up the
possibility of developing a continually updated atlas of infectious diseases.
N Freely available dynamic infectious disease risk maps would be valuable to a
wide range of health professionals from policy makers prioritizing limited
resources to individual clinicians.
Figure 1. A schematic overview of the process of predicting spatial disease risk. The
definitive extent of infectious disease occurrence at the national level (red is certain presence,
green is certain absence) [16] is combined with assemblies of known occurrence, presence points
(red dots), to generate putative pseudo-absence points (blue dots). The presence and pseudo-
absence data are then used in the analyses, with selected environmental covariates to predict
disease risk, formally the probability of occurrence of the target disease. In this example a risk map
of dengue is shown, shaded from low probability of occurrence in blue to high probability of
occurrence in red [8]. The arrows represent data flows.
doi:10.1371/journal.pmed.1001413.g001
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sources demonstrate significant noise and
require continual model fine tuning, the
sheer volume of health outcome related
searches and personal accounts presents
incredible new opportunities to monitor
population health in real time. It is less
well appreciated that this information
could also be used to build definitive
extents and databases on the occurrence
of many diseases [2]. The volume, veloc-
ity, and variety of occurrence information
from these sources will increase rapidly
and transform our ability to create geo-
graphical baselines for a range of diseases.
These novel data sources come with issues
of reliability so it is important that the
machine learning process is calibrated for
known reporting bias and the triage
process assigns a weighting to each data
point as a measure of reliability. This
weighting is an integral part of the niche
mapping techniques used and feeds into
the measure of uncertainty output for each
location. An increasing proportion of these
new data are geo-positioned at source.
Moreover, machine learning approaches
to automate geo-positioning of disease
reports [26], especially when combined
with human oversight and crowdsourcing
(outsourcing tasks online to volunteers)
[27,28], can further radically lower the
logistical barriers to positioning this infor-
mation.
In the era of satellite sensors, a diversity
of epidemiologically relevant environmen-
tal information can be sourced globally at
daily intervals [29]. Big Data volume,
velocity, and variety challenges are in-
volved in moving from the traditional
processing of synoptic averages of covar-
iates to harnessing a wider variety of
temporally rich information that can be
matched in time with the new occurrence
information. This closer temporal match-
ing of disease outbreaks with covariates
may improve the accuracy of mapping
models, allowing for the possibility of
seasonally tailored geographic baselines
and may help improve traditional tempo-
ral surveillance by facilitating early warn-
ing of epidemiologically relevant environ-
mental changes.
Perhaps the most important develop-
ment in relation to Big Data is the
conceptual move from static to improving
and evolving risk maps. Taking further our
example of dengue mapping (Figure 1),
the first evidence-based risk map generat-
ed can be used to help triage the
information content of new reports before
running the next map iteration. For
example, disease reports located nearby
existing records and with a high-predicted
probability of occurrence are not alarm-
ing; we expect the disease to occur here
from the history of reporting and the
suitability of the environment. Further-
more, such reports will not substantially
alter the risk map and are thus of low
priority to analysts. Conversely, a disease
outbreak far away from observed occur-
rence is alarming, and more so if it occurs
in an area biologically suitable for the
disease. It should be investigated and, if
verified, contribute to improving next
iterations of the map. It is easy to imagine
how these automated learning processes,
supervised by expert analysts, could be
deployed in tandem for all diseases of
concern, transforming our spatial intelli-
gence, surveillance, and preparedness.
The Challenges Ahead
The biggest obstacles to incorporating a
continuous spatial mapping component to
routine biosurveillance will be demonstrat-
ing the feasibility and sustainability of this
undertaking and engaging the audience.
We have focussed here on applications for
biosurveillance but it is important to
emphasise the wider audiences. First, one
should never underestimate the value of
risk maps in helping to illustrate the extent
of a public health problem [30]. Second,
addressing the paucity of spatial informa-
tion on infectious disease distributions will
transform our understanding of their envi-
ronmental determinants and help radically
improve our understanding of the factors
that promote disease diversity [31] and
emergence [32]. Third, a comprehensive
atlas of contemporary distributions would
be of considerable benefit to improvefuture
assessments of the burden of disease [33].
The audience for risk maps that are
continuous in time and space includes
agencies who need to prioritise limited
resources and respond to changing disease
patterns, public and private R&D pipelines
who need to assess value and plan research
strategy, logistics groups who need to
optimise the roll out of new interventions/
treatments, and clinicians who want to
accurately diagnose infectious diseases in
local populations and returning travellers.
We have already argued that this
mapping ambition is made tractable by
automating many of the laborious steps in
primary data acquisition and positioning.
The Big Data revolution is already
underway and harnessing the useful infor-
mation in these new data sources will
involve collaborations with computer sci-
entists at the forefront of machine learning
and with those who have had success in
engaging communities [27]. The evidence
shows that motivating people to devote
some of their ‘‘cognitive surplus’’ to crowd
sourcing is possible, so long as the products
and benefits are immediately available to
all for the common good. We have seen
the rise of crowdsourcing influenza sur-
veillance with participatory systems such
as Flu Near You in the United States
(www.flunearyou.org) and Influenzanet in
the EU (www.influenzanet.eu), which now
boast nearly 100,000 volunteers com-
bined. From the outset all infectious
disease data and derived maps should be
made freely available to ensure engage-
ment. This will also facilitate the uptake of
new resources and their consideration by
policy makers. Once the primary invest-
ment in the software platform is complete,
and the community established, sustain-
ability increases because demands for user
inputs decrease as the software learns and
the mapped outputs become increasingly
Table 1. An assessment of the challenges of using Big Data in disease mapping.
Definitive Extent Occurrence Point
Pseudo-Absence
Point Environmental Covariates Risk Prediction
Volume (scale) +++ +++ + +++ +++
Velocity (frequency) +++ +++ ++ +++ +++
Variety (diversity) ++ ++ + + +
The potential Big Data challenges in each stage of an iterative mapping process are highlighted in the table. The columns represent each of the mapping stages defined
in Figure 1. The rows reflect the volume, velocity, and variety descriptors of data contributions. The future Big Data challenge in relation to infectious disease risk
mapping is as follows: low (+), medium (++), and high (+++).
doi:10.1371/journal.pmed.1001413.t001
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tise the platform by providing the code to
all interested authorities.
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